Anticancer effects of combinational treatment with BRAF^V600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAF^V600E.

ABSTRACT: In the present study, the anti-tumor effects of combination treatment with an siRNA targeting B-Raf proto-oncogene serine/threonine kinase (BRAF)^V600E and phosphoinositide 3-kinase (PI3K) signaling pathway inhibitors was investigated in melanoma cell lines harboring BRAF^V600E. Human melanoma A375 and WM115 cells were treated with siRNA targeting to BRAF or BRAF^V600E, combined with treatment with PI3K signaling pathway inhibitors. CCK-8 and EdU proliferation assays were performed to assess cell viability and proliferation, respectively, following treatment. In addition, flow cytometry analysis was performed to determine cell cycle distribution, and western blot analysis was performed to analyze the activity of the extracellular signal-regulated kinase (ERK)

SUBMITTER: He H 

PROVIDER: S-EPMC6006476 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature